Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lipid Disorders Clear all
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

NCT01288469
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
20
States / cities
Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 17, 2026, 6:05 AM EDT
Recruiting No phase listed Observational

LCAT (Lecithin Cholesterol Acyl Transferase) Natural History Study

NCT06217588
View directory record Official record
Conditions
LCAT Deficiency
Interventions
Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
40 participants
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 17, 2026, 6:05 AM EDT
Terminated Phase 3 Interventional

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

NCT00729027
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
25 mg/day AVE5530, 50 mg/day AVE5530, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 17, 2026, 6:05 AM EDT
Terminated No phase listed Observational

Bile Acids in Acute Insulin Resistance

NCT05571670
View directory record Official record
Conditions
PI3K Gene Mutation, AKT Gene Mutation, MTOR Gene Mutation, Cancer, Insulin Resistance
Interventions
Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 17, 2026, 6:05 AM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-up of Subjects Who Were Treated With ST-920

NCT05039866
View directory record Official record
Conditions
Fabry Disease, Fabry Disease, Cardiac Variant
Interventions
ST-920
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2039
U.S. locations
8
States / cities
Irvine, California • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 17, 2026, 6:05 AM EDT
Recruiting No phase listed Observational

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742
View directory record Official record
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2034
U.S. locations
92
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 17, 2026, 6:05 AM EDT
Completed No phase listed Observational

Intravenous ACP-501 for Familial LCAT Deficiency (rhLCAT)

NCT04737720
View directory record Official record
Conditions
Familial LCAT Deficiency
Interventions
Recombinant LCAT
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Not applicable Interventional

Soybean Based Diets and CVD Risk Factors

NCT00175097
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Diet: soybeans and products made thereof, Diet: soybean flour and products made thereof, Diet: soybean milk, Diet: Animal protein based diet
Other
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Not applicable Interventional

Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease

NCT03492541
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Propylene glycol-based eye drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Kansas City, Missouri • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

NCT03611010
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemias
Interventions
Atorvastatin injection
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease

NCT06242860
View directory record Official record
Conditions
Evaporative Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
ELM
Device
Lead sponsor
Eyedetec Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Citrus Heights, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise After Clinically Significant Weight Loss

NCT03685123
View directory record Official record
Conditions
Obesity, Sedentary Lifestyle, Insulin Resistance
Interventions
Physical activity recommendations, Weight maintenance recommendations, OPTIFAST weight loss
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 17, 2026, 6:05 AM EDT
Recruiting Phase 3 Interventional

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Plozasiran Injection
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
869 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
71
States / cities
Bakersfield, California • Beverly Hills, California • Canoga Park, California + 62 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 17, 2026, 6:05 AM EDT
Recruiting Phase 3 Interventional

A Gaucher Disease Gene Therapy Trial With FLT201

NCT07223944
View directory record Official record
Conditions
Gaucher Disease Type 1
Interventions
FLT201
Genetic
Lead sponsor
Spur Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

NCT01550432
View directory record Official record
Conditions
Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
Interventions
Glutathione, N-Acetylcysteine, Placebo
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Hemoglobinopathy

NCT00176852
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome
Interventions
Busulfan, Fludarabine, ATG, TLI, Busulfan, Cyclophosphamide, ATG, GCSF, Campath, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem cell infusion
Drug · Radiation · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops

NCT03706443
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca, Lacrimal Apparatus Diseases, Keratoconjunctivitis, Eye Diseases, Keratitis, Corneal Disease, Ophthalmic Solution
Interventions
Systane Complete, Systane Ultra
Other
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

NCT02939547
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-beta-cyclodextrin
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Oakland, California • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Amino Acids on Regional Lipid Metabolism

NCT01150188
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Amino acids, Placebo
Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study on the Submental Area

NCT01859091
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The Zeltiq System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Not applicable Interventional

Process Versus Outcomes Incentives for Lipid Management

NCT02246959
View directory record Official record
Conditions
Diabetes, Cardiovascular Disease
Interventions
Process Incentive, Outcome Incentive
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 17, 2026, 6:05 AM EDT
Terminated Phase 1 Interventional Results available

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

NCT02231710
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies, Metabolic Disorders
Interventions
BPX-501 and Rimiducid
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
4 Months to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 17, 2026, 6:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects

NCT01806324
View directory record Official record
Conditions
Hypertension, Hyperlipidemia
Interventions
HL040XC, Losartan + Atorvastatin
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
19 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 17, 2026, 6:05 AM EDT